Bharat Biotech's vaccine Covaxin has shown the efficacy of 78 per cent against mild, moderate and severe cases of Covid-19, as per Phase III interim analysis results, the vaccine maker said on Wednesday. It further noted that the second interim data of the Phase III study also showed that chances of hospitalisation due to the infectious disease were reduced by 100 per cent after taking the Covaxin jab.